Skip to Content

Vimpat (lacosamide) Disease Interactions

There are 4 disease interactions with Vimpat (lacosamide):

Major

Anticonvulsants (applies to Vimpat) depression

Major Potential Hazard, Moderate plausibility.

Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication. Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior. Caregivers and family should be alert for the emergence or worsening of symptoms. Behaviors of concern should be reported immediately to the healthcare providers.

Moderate

Lacosamide (applies to Vimpat) CVD

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease, Heart Disease, Myocardial Infarction

Dose dependent prolongation in PR interval has been observed with the use of lacosamide. This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval. An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.

Moderate

Lacosamide (applies to Vimpat) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration. A maximum dose of 300 mg/day is recommended for these patients. Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.

Moderate

Lacosamide (applies to Vimpat) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease. Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure. Dose titration should be done with caution in all renally impaired patients.

Vimpat (lacosamide) drug interactions

There are 109 drug interactions with Vimpat (lacosamide)

Vimpat (lacosamide) alcohol/food interactions

There is 1 alcohol/food interaction with Vimpat (lacosamide)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.